A Case of Autoimmune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination

Cureus. 2021 May 15;13(5):e15035. doi: 10.7759/cureus.15035.


Autoimmune hemolytic anemia (AIHA) is a condition characterized by the increased destruction of red blood cells (RBCs) mediated by anti-erythrocyte autoantibodies with or without complement activation. Its clinical presentation is heterogeneous, ranging from asymptomatic to severe forms with fatal outcomes, and it can be either idiopathic or secondary to a coexisting disorder. In this report, we present a case of a patient who suffered from acute and severe AIHA after receiving the second dose of the coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine.

Keywords: autoimmune hemolytic anemia; covid-19 mrna vaccine; immune-mediated hemolysis; sars-cov-2; warm autoimmune hemolytic anemia.

Publication types

  • Case Reports